Would you still offer durvalumab after chemoradiation in patients with stage III NSCLC whose treatment was delayed due to prolonged recovery from chemoradiation?
At what point (ie 8, 10, 12 weeks or more) would you no longer offer consolidation durvalumab?
Community PollStarted
At what point would you NOT offer consolidation durvalumab in an otherwise eligible stage III NSCLC patient with no evidence of progression on restaging scans?
120 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Fox Chase Cancer Center
Answered on
The PACIFIC study, which evaluated the use of durvalamab after completion of chemotherapy and radiation (both sequential and concurrent) is a landmark trial demonstrating improved survival for those receiving immunotherapy. The design of the study required that durvalamab commence within 42 days of ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Wexner Medical Center at The Ohio State University
Answered on
In general, I would follow the entry/eligibility criteria as described in the PACIFIC trial - i.e. up to 42 days/six weeks after completion of chemoradiation (last dose of radiation). In fact, in the supplementary data from the 2018 NEJM report, there was a trend towards improvement in OS with treat...
Join for free or sign in to see the full answer